To find out more about cancer, we have provided links to
patient-focused cancer organizations. Note, that when you click
on the link you will be leaving the Jennerex website.
Hepatocellular carcinoma (HCC), which is the initial target of
Jennerex's lead product candidate, JX-594, is the fifth most
common cancer worldwide and the third leading cause of cancer
death, with over 600,000 new cases diagnosed annually resulting
in more than 90 percent mortality¹. The U.S. has witnessed a
three-fold increase in the incidence of HCC over the past
decade, and 20,000 new cases are now diagnosed with
approximately 18,700 deaths annually². HCC occurs more often in
men than women. It is usually seen in people ages 50 – 60 years
of age. The disease is more common in parts of Africa and Asia
than in North or South America and Europe. HCC is not the same
as metastatic liver cancer, which starts in another organ (such
as the breast or colon) and spreads to the liver. Patients with
hepatitis B or C are at risk for liver cancer,